KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline

Proceeds will enable further clinical development of DSP107, a first-in-class CD47x41BB targeting fusion protein, for the treatment of solid and hematological tumors and accelerate the path towards clinical development of the Company's preclinical pipeline... Biopharmaceuticals, Oncology, Venture Capital KAHR Medical, immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news